Diagnosing Lupus Nephritis: Decoding Your Kidney Biopsy
At a Glance
A kidney biopsy shows the type and severity of lupus-related kidney injury, including active inflammation, immune deposits, and permanent scarring. The report’s class and scores help doctors choose treatment and explain what the findings may mean for future kidney function.
While blood and urine tests provide important clues, they cannot tell the whole story of what is happening inside your kidneys. A kidney biopsy is considered the “gold standard” for diagnosis because lab results alone—such as protein levels or autoantibody counts—often fail to accurately predict the actual type and severity of kidney inflammation [1][2]. In fact, up to 11% of patients with suspected lupus nephritis (LN) are found to have a different condition entirely upon biopsy, while others with very low levels of protein in their urine may still have significant, hidden inflammation [3][1].
Because it is an invasive procedure, your nephrologist will carefully weigh the need for the biopsy (such as significant proteinuria, active urinary sediment, or an unexplained drop in kidney function) against risks like bleeding [1].
What to Expect During a Biopsy
A kidney biopsy is usually done in a hospital or clinic setting. You will be given local anesthesia to numb the area, and the doctor will typically use an ultrasound to guide a thin needle into the kidney to take a tiny sample of tissue. Afterward, you will lie flat for several hours to prevent bleeding. It is normal to have some mild soreness or a small amount of blood in your urine for a day or two, but severe pain or heavy bleeding requires immediate medical attention.
The Three Pillars of Your Report
A pathologist examines your kidney tissue using three distinct methods to create a complete picture:
- Light Microscopy: A traditional view of the kidney’s architecture and cells.
- Immunofluorescence (IF): Uses special dyes to see where immune proteins (like IgG, IgA, and C3) have “stuck” to the kidney. A classic finding in LN is “full-house” staining, where almost every immune protein tested is present [4][5]. While these findings support the diagnosis, they are not definitive proof on their own; full-house staining can sometimes occur in infections or other kidney conditions [6].
- Electron Microscopy (EM): A high-powered view that reveals tiny structures. Pathologists look for subendothelial deposits (immune clusters under the filter lining) and tubuloreticular inclusions—fingerprint-like structures inside blood vessel cells that strongly suggest lupus [4][7].
Decoding the ISN/RPS Classes
Your report will assign your condition to one of six classes, which helps your doctor determine the best treatment approach [8]:
- Class I & II (Minimal/Mesangial): Early or mild changes in the kidney’s central support tissue.
- Class III & IV (Proliferative): These are the most aggressive forms. They involve significant inflammation and “proliferation” (overgrowth) of cells in the filters. Class IV is more widespread than Class III. These classes require intensive treatment to prevent scarring [8][9].
- Class V (Membranous): The filters become thickened as immune complexes build up on the outside of the filter wall. This often leads to severe protein leakage (nephrotic syndrome) [7][10].
- Class VI (Advanced Sclerosis): Represents advanced, permanent scarring where most of the kidney’s filters are no longer functional [8].
Mixed Patterns: It is common to have a “mixed” diagnosis, such as Class III+V or IV+V, meaning you have features of both proliferative and membranous disease [11].
Activity vs. Chronicity: The NIH Indices
Beyond the class, your report will include two vital scores that measure the state of your kidneys [12][8]:
- Activity Index (Score 0–24): This measures active inflammation. High scores mean the disease is “active” and likely to respond to immunosuppressant medications. Key active lesions include fibrinoid necrosis (cell death) and crescents (rapid cell growth in the filter) [8][13]. However, note that while active lesions may respond to treatment, they can sometimes still leave behind permanent scars.
- Chronicity Index (Score 0–12): This measures established scarring. It tracks permanent damage like interstitial fibrosis (scarring between the filters) and tubular atrophy. This score helps your doctor understand the long-term outlook for your kidney function, though it does not dictate your exact prognosis on its own [14][15].
When It’s Not “Typical” Lupus Nephritis
Sometimes, the biopsy reveals “look-alike” conditions or complications that require different care:
- Lupus Podocytopathy: A rare variant where the kidney filters look mostly normal under light microscopy, but the specialized cells (podocytes) are severely damaged. It causes heavy protein leakage but lacks the typical “immune complex” clusters [16].
- Antiphospholipid Nephropathy: Damage to the small blood vessels of the kidney, often seen in patients who also have antiphospholipid syndrome. This involves tiny clots rather than just inflammation [17].
- Other Mimics: Infections (like syphilis or viruses) and even other autoimmune diseases like IgA Nephropathy can sometimes mimic the “full-house” look of lupus [18][19].
Checklist: Is Your Report Complete?
A high-quality pathology report should explicitly mention the following:
- [ ] ISN/RPS Class (I through VI) [8]
- [ ] NIH Activity Index (with specific mention of crescents or necrosis) [12]
- [ ] NIH Chronicity Index (especially the degree of interstitial fibrosis) [12]
- [ ] Immunofluorescence findings (checking for “full-house” proteins) [4]
- [ ] Electron Microscopy findings (checking for deposits and podocyte health) [7]
- [ ] Vascular status (checking for clots or vessel inflammation) [14]
- [ ] Sample adequacy (confirming enough tissue was collected to make a diagnosis)
Common questions in this guide
Why do I need a kidney biopsy for lupus nephritis?
What do the ISN/RPS classes mean in a lupus nephritis report?
What are the activity and chronicity scores in lupus nephritis?
Does full-house staining confirm lupus nephritis?
What happens during and after a lupus nephritis kidney biopsy?
What should be included in my lupus nephritis pathology report?
One line in your results can change your plan.
The biopsy class helps your doctor determine the treatment approach for lupus nephritis. We check your results against the latest research to help you prepare for what’s next.
Get notified when new evidence is published on Lupus nephritis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (19)
- 1
Low-Level Proteinuria in Systemic Lupus Erythematosus.
Chedid A, Rossi GM, Peyronel F, et al.
Kidney international reports 2020; (5(12)):2333-2340 doi:10.1016/j.ekir.2020.09.007.
PMID: 33305127 - 2
Development of an instrument to predict proliferative histological class in lupus nephritis based on clinical and laboratory data.
Silaide de Araújo Júnior A, Sato EI, Silva de Souza AW, et al.
Lupus 2023; (32(2)):216-224 doi:10.1177/09612033221143933.
PMID: 36461171 - 3
New age of Lupus Nephritis: Updates in guidelines, biomarkers, and therapies.
Ibrahim M, He E, Tran D, et al.
Best practice & research. Clinical rheumatology 2026; (40(3)):102153 doi:10.1016/j.berh.2026.102153.
PMID: 42097966 - 4
Sensitivity and Specificity of Pathologic Findings to Diagnose Lupus Nephritis.
Kudose S, Santoriello D, Bomback AS, et al.
Clinical journal of the American Society of Nephrology : CJASN 2019; (14(11)):1605-1615 doi:10.2215/CJN.01570219.
PMID: 31653670 - 5
Analysis of the Sensitivity and Specificity of Histopathological Findings for Diagnosing Lupus Nephritis.
da Luz Neto ER, Tavares MB, de Melo AGJT, et al.
Diagnostics (Basel, Switzerland) 2024; (14(23)) doi:10.3390/diagnostics14232681.
PMID: 39682589 - 6
Clinicopathological Pattern of Non-lupus Full House Nephropathy.
Wani AS, Zahir Z, Gupta A, Agrawal V
Indian journal of nephrology 2020; (30(5)):301-306 doi:10.4103/ijn.IJN_91_18.
PMID: 33707816 - 7
Lupus Membranous Nephropathy.
Ponticelli C, Moroni G, Fornoni A
Glomerular diseases 2021; (1(1)):10-20 doi:10.1159/000512278.
PMID: 36751488 - 8
Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices.
Bajema IM, Wilhelmus S, Alpers CE, et al.
Kidney international 2018; (93(4)):789-796 doi:10.1016/j.kint.2017.11.023.
PMID: 29459092 - 9
Current treatment of lupus nephritis: an overview of the new guidelines.
Sales GTM, Macedo NJ, Reis Neto ETD, Kirsztajn GM
Jornal brasileiro de nefrologia 2025; (47(4)):e20250092 doi:10.1590/2175-8239-JBN-2025-0092en.
PMID: 41082628 - 10
Membranous Lupus Nephritis: A Clinical Review.
Almaani S, Parikh SV
Advances in chronic kidney disease 2019; (26(5)):393-403 doi:10.1053/j.ackd.2019.08.009.
PMID: 31733724 - 11
Comparison of Outcomes between Individuals with Pure and Mixed Lupus Nephritis: A Retrospective Study.
Ilori TO, Enofe N, Oommen A, et al.
PloS one 2016; (11(6)):e0157485 doi:10.1371/journal.pone.0157485.
PMID: 27304068 - 12
Histologic evaluation of activity and chronicity of lupus nephritis and its clinical significance.
Choi SE, Fogo AB, Lim BJ
Kidney research and clinical practice 2023; (42(2)):166-173 doi:10.23876/j.krcp.22.083.
PMID: 37037479 - 13
Inter-observer variability of the histological classification of lupus glomerulonephritis in children.
Oni L, Beresford MW, Witte D, et al.
Lupus 2017; (26(11)):1205-1211 doi:10.1177/0961203317706558.
PMID: 28478696 - 14
Kidney Biopsy and Prognosis in Lupus Nephritis: Histological Predictors of Renal Outcome-A Narrative Review.
Rossi GM, Pala C, Fontana F, et al.
Medicina (Kaunas, Lithuania) 2026; (62(9)) doi:10.3390/medicina62091653.
PMID: 42796262 - 15
Clinical characteristics and renal prognosis associated with interstitial fibrosis and tubular atrophy (IFTA) and vascular injury in lupus nephritis biopsies.
Leatherwood C, Speyer CB, Feldman CH, et al.
Seminars in arthritis and rheumatism 2019; (49(3)):396-404 doi:10.1016/j.semarthrit.2019.06.002.
PMID: 31277928 - 16
Lupus Podocytopathy: An Overview.
Oliva-Damaso N, Payan J, Oliva-Damaso E, et al.
Advances in chronic kidney disease 2019; (26(5)):369-375 doi:10.1053/j.ackd.2019.08.011.
PMID: 31733721 - 17
Anti-pentraxin 3 auto-antibodies might be protective in lupus nephritis: a large cohort study.
Yuan M, Tan Y, Pang Y, et al.
Renal failure 2017; (39(1)):465-473 doi:10.1080/0886022X.2017.1308258.
PMID: 28393653 - 18
An Interesting Case of Nonlupus Full-House Nephropathy.
Sathi S, Sharma A, Garg AK, et al.
Case reports in nephrology 2021; (2021()):9043003 doi:10.1155/2021/9043003.
PMID: 34992890 - 19
Syphilis and parvovirus B19 co-infection imitating a lupus nephropathy: A case report.
Jaunin E, Kissling S, Rotman S, et al.
Medicine 2019; (98(36)):e17040 doi:10.1097/MD.0000000000017040.
PMID: 31490394
This page explains kidney biopsy findings in lupus nephritis for informational purposes only and does not constitute medical advice. Ask your nephrologist or care team to interpret your report and discuss your next steps.